Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Role of Opioids in Patients With Chronic Obstructive Pulmonary Disease and Chronic Breathlessness

The Role of Opioids in Patients With Chronic Obstructive Pulmonary Disease and Chronic... Effect of Sustained-Release Morphine on Patients With COPD and Refractory Breathlessness Original Investigation Research Invited Commentary The Role of Opioids in Patients With Chronic Obstructive Pulmonary Disease and Chronic Breathlessness Eric W. Widera, MD In 1981, Woodcock and colleagues published the first clini- tain. Although the trial was designed to detect a minimal clini- cal study of opioids for the management of breathlessness in cally important difference of 3.8 points in the CAT, the au- severe chronic obstructive pulmonary disease (COPD). They thors found a difference of only 2.18. However, Verberkt et al found that dihydrocodeine offered a short-term benefit but concluded that their findings were clinically relevant based on cautioned readers that “the a 2017 study which found that the minimal clinically impor- risks of respiratory depres- tant difference for the CAT was between 2 and 3 points. It is Related article page 1306 sion and addiction” necessi- reasonable to use the most current evidence to help interpret tate careful monitoring and patient selection and that more findings; however, lowering the threshold that defines a clini- 1(p1616) studies were needed prior to “haphazard prescribing.” cally meaningful difference at the end of the study suggests Over the course of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

The Role of Opioids in Patients With Chronic Obstructive Pulmonary Disease and Chronic Breathlessness

JAMA Internal Medicine , Volume 180 (10) – Oct 17, 2020

Loading next page...
 
/lp/american-medical-association/the-role-of-opioids-in-patients-with-chronic-obstructive-pulmonary-dAs5SZ5ZEH
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2020.3133
Publisher site
See Article on Publisher Site

Abstract

Effect of Sustained-Release Morphine on Patients With COPD and Refractory Breathlessness Original Investigation Research Invited Commentary The Role of Opioids in Patients With Chronic Obstructive Pulmonary Disease and Chronic Breathlessness Eric W. Widera, MD In 1981, Woodcock and colleagues published the first clini- tain. Although the trial was designed to detect a minimal clini- cal study of opioids for the management of breathlessness in cally important difference of 3.8 points in the CAT, the au- severe chronic obstructive pulmonary disease (COPD). They thors found a difference of only 2.18. However, Verberkt et al found that dihydrocodeine offered a short-term benefit but concluded that their findings were clinically relevant based on cautioned readers that “the a 2017 study which found that the minimal clinically impor- risks of respiratory depres- tant difference for the CAT was between 2 and 3 points. It is Related article page 1306 sion and addiction” necessi- reasonable to use the most current evidence to help interpret tate careful monitoring and patient selection and that more findings; however, lowering the threshold that defines a clini- 1(p1616) studies were needed prior to “haphazard prescribing.” cally meaningful difference at the end of the study suggests Over the course of

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Oct 17, 2020

References